TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33802870

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention providing 8 weeks of tailored psychosocial support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 0
Study: 35051993

Group type: EXPERIMENTAL
Intervention: Virtual Reality Intervention for Safety Education (VRISE)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control1: No treatment group
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control2: 2D Screen group
Number of subjects: 291
Study: 33629189

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX) and Placebo
Number of subjects: 356
Study: 32240304

Group type: EXPERIMENTAL
Intervention: Plumpy'doz
Number of subjects: 3592

Group type: EXPERIMENTAL
Intervention: Chickpea
Number of subjects: 3592

Group type: EXPERIMENTAL
Intervention: Rice-lentil
Number of subjects: 3592

Group type: EXPERIMENTAL
Intervention: WSB++
Number of subjects: 3592

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3592
Study: 35544042

Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP vaccine (3 × 105 to 1 × 108 pfu)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP vaccine
Number of subjects: 354
Study: 32979429

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 69
Study: 34273124

Group type: EXPERIMENTAL
Intervention: High fruit and vegetable consumption
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: High fruit and vegetable consumption with high fat intake
Number of subjects: 240
Study: 32406918

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 30
Study: 35296253

Group type: EXPERIMENTAL
Intervention: Dynamic individualized PEEP titration (DV group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Constant PEEP (PV group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Zero PEEP (CV group)
Number of subjects: 51
Study: 33422683

Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 44

Group type: COMPARATOR
Intervention: sham-stimulation
Number of subjects: 44
Study: 35951718

Group type: EXPERIMENTAL
Intervention: Risuteganib (1.0 mg intravitreal injection)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 39
Study: 33245129

Group type: EXPERIMENTAL
Intervention: Tubaramure program (food rations, BCC)
Number of subjects: 2620

Group type: EXPERIMENTAL
Intervention: Tubaramure program (T18: food rations from pregnancy to 18 months)
Number of subjects: 2620

Group type: EXPERIMENTAL
Intervention: Tubaramure program (T24: food rations from pregnancy to 24 months)
Number of subjects: 2620

Group type: EXPERIMENTAL
Intervention: Tubaramure program (treatment arms combined)
Number of subjects: 2620

Group type: COMPARATOR
Intervention: Control group (no rations or BCC)
Number of subjects: 2620
Study: 35814746

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided preoperative thoracic paravertebral blocks (TPVB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intercoastal nerve blocks (ICNB)
Number of subjects: 100
Study: 34218329

Group type: EXPERIMENTAL
Intervention: CADe-first group
Number of subjects: 358

Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)-first group
Number of subjects: 358
Study: 32178978

Group type: EXPERIMENTAL
Intervention: VENTANA SP142
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: VENTANA SP263
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: DAKO 22C3
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: DAKO 28-8
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: All 4 assays
Number of subjects: 201
Study: 35576276

Group type: EXPERIMENTAL
Intervention: Microporous tape applied to scars for six months, worn twenty-four hours daily, changed every fortnight.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-taped scars
Number of subjects: 0
Study: 33509268

Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques (TRT) and In‐service Teacher Training (INSETT)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Wait-list control (services as usual)
Number of subjects: 350
Study: 32553596

Group type: EXPERIMENTAL
Intervention: IC injection of CD133+ BMSC
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 35247847

Group type: EXPERIMENTAL
Intervention: 3 g/day of fish oil concentrate (providing 1.1 g eicosapentaenoic acid (EPA) + 0.8 g docosahexaenoic acid (DHA))
Number of subjects: 84

Group type: COMPARATOR
Intervention: 3 g/day of corn oil
Number of subjects: 84
Study: 34723443

Group type: EXPERIMENTAL
Intervention: HP4%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MA + HP4%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HP10%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MA + HP10%
Number of subjects: 40
Study: 33578519

Group type: EXPERIMENTAL
Intervention: Micro-video intervention via WeChat
Number of subjects: 78

Group type: COMPARATOR
Intervention: Routine off-line instruction
Number of subjects: 78
Study: 32122797

Group type: EXPERIMENTAL
Intervention: PARO (robotic seal)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study: 34931276

Group type: EXPERIMENTAL
Intervention: Food-specific EEG neurofeedback paradigm
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: General EEG neurofeedback paradigm
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both EEG neurofeedback paradigms
Number of subjects: 39
Study: 33316077

Group type: EXPERIMENTAL
Intervention: IgG subclasses presence
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IgG2 subclass
Number of subjects: 43
Study: 35850080

Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) 3 g/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Olive Oil (OO) 3 g/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 43
Study: 33277777

Group type: EXPERIMENTAL
Intervention: Challenges linked to participant co‐morbidities
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Challenges linked to participant ability levels
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Challenges linked to ethics and consent
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Challenges linked to RCT methodology
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Challenges linked to gatekeeping
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Challenges linked to staff turnover
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Challenges linked to lack of technical understanding
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Challenges linked to attitudes and perceptions
Number of subjects: 12
Study: 32193382

Group type: EXPERIMENTAL
Intervention: Healthful dietary pattern driven by wholemeal vs. white bread consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary patterns derived from food frequency questionnaires
Number of subjects: 0
Study: 34156877

Group type: EXPERIMENTAL
Intervention: Arthroscopic nerve release during rotator cuff repair
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (arthroscopic repair of the rotator cuff without nerve release)
Number of subjects: 42
Study: 32990630

Group type: EXPERIMENTAL
Intervention: Hep‐Net intervention
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 235
Study: 34545613

Group type: EXPERIMENTAL
Intervention: 1 finger‐tip unit equivalent dose of Hirudoid Cream 0.3% applied twice daily for 28 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1/3 finger‐tip unit equivalent dose of Hirudoid Cream 0.3% applied twice daily for 28 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 finger‐tip unit equivalent dose of Hirudoid Cream 0.3%
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1/3 finger‐tip unit equivalent dose of Hirudoid Cream 0.3%
Number of subjects: 60
Study: 34296782

Group type: EXPERIMENTAL
Intervention: Unique unrelated question randomized response model
Number of subjects: 0
Study: 32569087

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo treatment in first treatment period
Number of subjects: 318

Group type: COMPARATOR
Intervention: Trial-specific factors (treatment sequence, chance of having placebo treatment)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Patient-specific factors (age, sensory signs, pain symptoms)
Number of subjects: 318
Study: 35133516

Group type: EXPERIMENTAL
Intervention: HBOT (two absolute atmospheres (ATA), breathing 100% oxygen for 1 h)
Number of subjects: 37
Study: 34863239

Group type: EXPERIMENTAL
Intervention: rESWT
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: rESWT + C + E
Number of subjects: 140

Group type: COMPARATOR
Intervention: C + E
Number of subjects: 140
Study: 35640225

Group type: COMPARATOR
Intervention: Standard behavioral weight loss treatment (BT)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: BT with a focus on physical activity (PA)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Acceptance-based therapy (ABT) with a focus on PA
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: High physical activity engagement
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Low emotional eating
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Belief that exercise does not affect appetite
Number of subjects: 320
Study: 33900585

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 0
Study: 32629291

Group type: EXPERIMENTAL
Intervention: Online cognitive training focused on executive functioning
Number of subjects: 228

Group type: COMPARATOR
Intervention: Online cognitive training focused on other cognitive abilities (Control)
Number of subjects: 228
Study: 34599401

Group type: EXPERIMENTAL
Intervention: Low-energy laser therapy (LLT) plus exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercises alone (control group)
Number of subjects: 60
Study: 32951632

Group type: EXPERIMENTAL
Intervention: CPAP plus usual care
Number of subjects: 2687

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 2687
Study: 35759949

Group type: EXPERIMENTAL
Intervention: Multithematic health coaching
Number of subjects: 149

Group type: COMPARATOR
Intervention: Smoking cessation counselling
Number of subjects: 149
Study: 34641941

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) therapy after static stretching
Number of subjects: 22

Group type: COMPARATOR
Intervention: Stretching only
Number of subjects: 22
Study: 32433273

Group type: EXPERIMENTAL
Intervention: LFD/B-GOS (1.4 g/d)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (sham diet with placebo supplement)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: LFD
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: LFD/B-GOS
Number of subjects: 69
Study: 35899378

Group type: EXPERIMENTAL
Intervention: Rozibafusp alfa (n = 26, doses of 70, 140, 210, and 420 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rozibafusp alfa (210 and 420 mg cohorts)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rozibafusp alfa (all cohorts)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rozibafusp alfa (n = 26)
Number of subjects: 34
Study: 32654554

Group type: EXPERIMENTAL
Intervention: High dose carbidopa (600 mg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low dose carbidopa (300 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 33762233

Group type: EXPERIMENTAL
Intervention: Gain-framed communication strategy
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Loss-framed communication strategy
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Long-term context communication strategy
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Short-term context communication strategy
Number of subjects: 15000
Study: 33271745

Group type: EXPERIMENTAL
Intervention: Zinc‐carbonate‐hydroxyapatite nanoparticle (CHA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Calcium sodium phosphosilicate bioactive glass (CSPS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Herbal based toothpaste (HB)
Number of subjects: 25
Study: 34990262

Group type: COMPARATOR
Intervention: Low-dose ara-C (LDAC, n=91)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard Ara-C, daunorubicin and etoposide (ADE, n=465)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Augmented high-dose ara-C (HDAC, n=75)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Augmented ADE + gemtuzumab ozogamicin (GO, n=466)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Augmented therapy (AML02-HDAC or AAML0531-ADE + GO)
Number of subjects: 166
Study: 34959850

Group type: EXPERIMENTAL
Intervention: Partially‐hydrolysed guar gum (PHGG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gum Arabic
Number of subjects: 10

Group type: COMPARATOR
Intervention: Psyllium husk
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study: 32641097

Group type: EXPERIMENTAL
Intervention: Central collection of screening logs
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Approach rate
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Acceptance rate
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Reason for declining trial participation
Number of subjects: 1138
Study: 35111274

Group type: EXPERIMENTAL
Intervention: MPM (paracetamol, ibuprofen, and arm physiotherapy)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Pain medication 'as needed' (Control)
Number of subjects: 137
Study: 34304728

Group type: EXPERIMENTAL
Intervention: Contradictory message condition
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Non-contradictory message condition
Number of subjects: 763

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 763
Study: 32407137

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) herbal formula, consumed twice daily for 3 months
Number of subjects: 79
Study: 35549845

Group type: EXPERIMENTAL
Intervention: T2LOW exacerbations
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: T2HIGH exacerbations
Number of subjects: 301
Study: 33771848

Group type: EXPERIMENTAL
Intervention: Personalized advice based on cancer risk prediction
Number of subjects: 5984

Group type: COMPARATOR
Intervention: Standard advice without risk prediction
Number of subjects: 5984
Study: 34951009

Group type: EXPERIMENTAL
Intervention: TP53 mutated patients
Number of subjects: 125

Group type: COMPARATOR
Intervention: TP53 wild-type patients
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: TP53 mutations
Number of subjects: 125
Study: 33227506

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35183232

Group type: EXPERIMENTAL
Intervention: Tai Chi combined with Kinesio taping (TC+KT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo Kinesio taping (TC+KTp)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Kinesio taping (KT)
Number of subjects: 53
Study: 32279145

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 16
Study: 35843174

Group type: EXPERIMENTAL
Intervention: NAB-PTX (nanoparticle albumin bound paclitaxel) administered via PIPAC at doses escalated from 35 to 140 mg/m2, with three treatments at four-week intervals.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: NAB-PTX (nanoparticle albumin bound paclitaxel) administered via PIPAC.
Number of subjects: 23
Study: 32924749

Group type: EXPERIMENTAL
Intervention: Psychological intervention with parents
Number of subjects: 66

Group type: COMPARATOR
Intervention: Urotherapy orientation and psychological counseling (control group)
Number of subjects: 66
Study: 32600406

Group type: EXPERIMENTAL
Intervention: Escalating doses of a nicotine patch (up to 84 mg)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Matching placebo patches
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patch
Number of subjects: 400
Study: 36258654

Group type: EXPERIMENTAL
Intervention: LivingWith® app used weekly for 3 months
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no app usage)
Number of subjects: 224
Study: 33651007

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (posttetanic count 1 to 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Number of subjects: 0
Study: 32028926

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) delivered via a mobile app (Manaaki) with six intervention modules, personalized feedback, and various engagement features.
Number of subjects: 284

Group type: COMPARATOR
Intervention: Waitlist group receiving a simple app that counts down to access the full app.
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) delivered via a mobile app (Manaaki).
Number of subjects: 284
Study: 35180555

Group type: EXPERIMENTAL
Intervention: Combined risk messages
Number of subjects: 1004

Group type: COMPARATOR
Intervention: COVID-19 risk condition
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Smoking risk condition
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1004
Study: 32770685

Group type: COMPARATOR
Intervention: Ablative fractional carbon dioxide (FCO2) laser
Number of subjects: 60

Group type: COMPARATOR
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of FCO2 laser and PRP
Number of subjects: 60
Study: 34684862

Group type: EXPERIMENTAL
Intervention: Iron-rice (IR) drink (15 mg iron/serving) consumed by anemic group (C) for 30 days
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Iron-rice (IR) drink (27 mg iron/serving) consumed by non-anemic group (D) for 30 days
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Iron-rice (IR) drink (15 mg iron/serving) consumed by non-anemic group (A) for 30 days
Number of subjects: 4

Group type: COMPARATOR
Intervention: WR drink (2 mg iron/serving) consumed by non-anemic group (A) for 30 days
Number of subjects: 4
Study: 32130679

Group type: EXPERIMENTAL
Intervention: FDC of ibuprofen/acetaminophen 250/500 mg (two tablets of ibuprofen 125 mg/acetaminophen 250 mg)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: FDC of ibuprofen/acetaminophen 250/500 mg with food
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: FDC of ibuprofen/acetaminophen 250/500 mg in adolescents
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: FDC of ibuprofen/acetaminophen 250/500 mg in adolescents aged 12-14 years
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: FDC of ibuprofen/acetaminophen 250/500 mg
Number of subjects: 102
Study: 34628687

Group type: EXPERIMENTAL
Intervention: CAL/BDP PAD-cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: CAL/BDP TS (active control)
Number of subjects: 0
Study: 34014758

Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276

Group type: COMPARATOR
Intervention: Sleep deprivation
Number of subjects: 276
Study: 34271782

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4) as intravenous infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard management without magnesium sulphate)
Number of subjects: 0
Study: 32297646

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 10
Study: 615919038

Group type: EXPERIMENTAL
Intervention: Right lateral decubitus position (RLD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Left lateral decubitus position (LLD)
Number of subjects: 15
Study: 34719101

Group type: EXPERIMENTAL
Intervention: 308-nm excimer light with bi-weekly intradermal PRP (group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 308-nm excimer light alone (group B)
Number of subjects: 36
Study: 33229305

Group type: EXPERIMENTAL
Intervention: Nurse-led hospital-to-home bridging program with 4 weeks postdischarge follow-up (2 home visits and 2 telephone calls)
Number of subjects: 705

Group type: COMPARATOR
Intervention: Control condition (standard care)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Nurse-led hospital-to-home bridging program
Number of subjects: 705
Study: 33823129

Group type: EXPERIMENTAL
Intervention: DS‐Cav1 vaccination
Number of subjects: 6
Study: 32436964

Group type: EXPERIMENTAL
Intervention: Hem‐o‐lok clips
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracorporeal knotting
Number of subjects: 0
Study: 35409872

Group type: EXPERIMENTAL
Intervention: Diabetes-specific meal replacement (MR) replacing one meal for 5 days a week for 12 weeks
Number of subjects: 156

Group type: COMPARATOR
Intervention: Routine dietary consultation
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Diabetes-specific meal replacement (MR)
Number of subjects: 156
Study: 32264769

Group type: EXPERIMENTAL
Intervention: Adolescents at risk for suicide
Number of subjects: 166

Group type: COMPARATOR
Intervention: Comparison group (matched by age and gender)
Number of subjects: 166
Study: 32350903

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Oral hygiene instructions (Control)
Number of subjects: 58
Study: 34961645

Group type: EXPERIMENTAL
Intervention: Computer‐assisted navigation systems (CANS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional surgical treatment without CANS
Number of subjects: 38
Study: 34225302

Group type: EXPERIMENTAL
Intervention: CRT+LE
Number of subjects: 79

Group type: COMPARATOR
Intervention: TME
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study: 36206822

Group type: EXPERIMENTAL
Intervention: Placebo beverage consumption
Number of subjects: 22
Study: 32838641

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 134
Study: 32445247

Group type: EXPERIMENTAL
Intervention: Intralesional injections (ILIs) of triamcinolone acetonide (TA) combined with extracorporeal shock wave therapy (ESWT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intralesional injections (ILIs) of triamcinolone acetonide (TA) alone
Number of subjects: 40
Study: 34996693

Group type: EXPERIMENTAL
Intervention: Cycling exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Repetitive nerve stimulation (RNS)
Number of subjects: 10